Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of PF-06260414 in Healthy Western and Japanese Males
NCT02070939Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06260414 in cachexia and Sarcopenia (6 arms), sponsored by Pfizer. Primary endpoints: Changes from baseline vital signs at 6 weeks, Changes from baseline in 12-lead ECG parameters at 6 weeks and 6 more. Started Feb 2014; status: completed.
02
Drugs
PF-06260414
03
Conditions
cachexiaSarcopenia
Beyond the preview
Go deeper on NCT02070939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02070939.